The Surefire Medical Blog
Clinical news, liver cancer topics, technology updates and Surefire Medical events.
Surefire will now market the Surefire Precision 021, Surefire Infusion System mT/LT, and Surefire Guiding Catheters in Mexico
Clinical Data Shows Surefire Technology Achieved 79% Objective Response versus 37% Using a Standard Microcatheter in Treating Primary Liver Cancer. Study presented at SIR 2017 Annual Scientific Meeting.
The New Flexion Guiding Catheter Includes a Nitinol Tip for Better Shape Retention and Improved Back-up Support
Multiple clinical studies verify significantly better liver cancer outcomes with use of unique expandable tip infusion systems
Surefire Medical, Inc. today announced that Mats Wahlström is joining the company’s Board of Directors and will serve as chairman.
Surefire to Collaborate with Roger Williams Medical Center and University of Colorado School of Medicine
Surefire Medical, Inc. today announced that Amy Davalle joined the company as the Vice President of Sales for North America.
German Classification Code issued, allows for tracking and measuring use of Surefire devices
Surefire Precision Infusion System was associated with a 68 percent complete tumor response and 92 percent objective tumor response
Please join us for our Scientific Symposium on Sept. 10 (Auditorium 2) and at Booth 53 at the Centre de Convencions Internacional de Barcelona to learn about our new products and clinical data.
Increased length and 1200 PSI rating provides for additional access in patient procedures and enables higher injection pressure for improved angiographic imaging.
Study presented at SIR shows Surefire Medical technology achieves 80% complete tumor response, effective in downstaging patients to transplant.
Led by Tullis Health Investors, the round will be used for a global launch of the new Surefire Precision Infusion System.
The new technology will be displayed at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2015 Scientific Meeting in Lisbon, Portugal.
The direct-to-tumor embolization device represents a new class of delivery devices employed in minimally invasive chemoembolization and radioembolization procedures.
Company receives the Jefferson County Economic Development Corporation’s Innovative Technology Award.
Trial Comparing the Surefire Infusion System to an end hole catheter finds improved tumor uptake (68%) and reduced non-target embolization (58%) in every patient.
General and cancer care hospitals ranked as ‘best hospitals’ by U.S. News & World Report use the technologically advanced Surefire Infusion System.
Ms. Huss is President and CEO of therapeutic temperature management startup QooL Therapeutics and brings experience developing minimally invasive approaches to treating obesity.
Program supports new fellows in the Interventional Radiology community and highlights relevant clinical experiences with advanced treatment technology
James E. Chomas honored as 2014 award finalist in the Mountain Desert Region
Early observations from the first direct comparison of the Surefire Infusion System vs. a standard end hole catheter in vivo to be presented at GEST
Radioembolization procedure time, contrast dose use cut in half; fluoroscopic time reduced by 70%
Axis, Cobra 1 and Simmons 1 are designed to provide physicians far greater ease in gaining access to patients’ peripheral blood vessels
Study evaluates eliminating coiling through use of the Surefire Infusion System in radioembolization procedures
Super Angel investors join MCG Partners, Partisan Management Group and High Country Ventures in funding Surefire Medical’s breakthrough infusion system
Designed for super selective embolization, the mT incorporates Surefire’s new low profile and effortlessly deployed expandable tip technology for maximum dose delivery without reflux
Six CIRSE presentations confirm procedural and cost-savings advantages of the Surefire Infusion System in cancer treatment
Gordon McLennan, MD, of the Cleveland Clinic and Fred Moeslein, MD, PhD of the University of Maryland Medical Center named to the Surefire Medical Scientific Advisory Board
NIH-funded study at Johns Hopkins Medicine will use the Surefire Medical Infusion System to develop minimally invasive treatment as an alternative to bariatric surgery
The new Surefire ST and LT systems are designed to maximize targeted delivery of embolics without reflux
New study shows Surefire Medical Infusion System maximizes drug direct-to-tumor drug delivery while protecting healthy tissue
The company’s global expansion continues with regulatory approval in New Zealand
The Colorado BioScience Association ‘Rising Star’ Award recognizes an emerging company that announced a major achievement during the year
Surefire Medical Infusion Systems are used in many hospitals ranked by U.S. News & World Report as the country’s best
Successful procedure was performed by Tobias Jakobs, MD of Krankenhaus Barmherzige Brueder in Munich, Germany.
McGrevin brings large-company senior management experience and a background in the expansion and sale of medical startups to Surefire Medical
Company to launch next-generation device for chemo- and radioembolization in Europe immediately
New system’s infusion efficiency exceeds 99 percent; designed to significantly reduce backflow
Dozens of high-volume hospitals have used the Surefire Infusion System, primarily in interventional procedures aimed at treating liver and kidney cancer
The company successfully implemented a limited launch of its novel infusion system in several key U.S. hospitals
Round led by Partisan Management Group, with additional investment from High Country Ventures and a small team of super angel investors.
The novel infusion system is the first catheter designed to deliver embolization agents with unhindered forward flow while preventing reflux
Mark Lupa, PhD, serves as managing director of High Country Venture, and Ginger L. Graham is the former president and chief executive officer of Amylin Pharmaceuticals